Phase III
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.
Biohaven Pharmaceutical announced positive topline data from its Phase III trial of oral rimegepant (Nurtec) for preventing migraine headaches in both episodic and chronic migraine patients.
AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
The World Health Organization is launching a clinical trial in Norway and Spain to assess four of the most promising drugs in the fight against COVID-19, the disease caused by the novel coronavirus that has spread across the globe.
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
Difamilast is a novel atopic dermatitis compound discovered by Otsuka.
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
PRESS RELEASES